It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Tailored biochemical assays deliver high-quality, decision-driving data, designed around your target, built for speed and powered by collaborative science.
Biochemical assays at Sygnature span a wide range of enzyme targets and discovery stages, from early hit identification to in vivo validation. Our scientists combine deep expertise with tailored design to build assays that match your target biology and program goals.
Every program begins with a conversation. We take time to understand your assay requirements and preferred modality of target interaction. From there, we select the most suitable assay technology and optimize parameters to balance sensitivity, signal window, and robustness. Where needed, we can bias the assay toward identifying molecules interacting via a specific mechanism of action.
Our optimization process includes defining the ideal buffer composition, calculating substrate Kₘ values, and identifying the lowest enzyme concentration that maintains linearity and reliability. During validation, we assess tool compound behavior and evaluate robustness, reproducibility, and plate effects.
Assay sensitivity is critical. Our experienced team can develop custom assays or refine commercial kits to ensure optimal data output. Whether your assays are continuous or endpoint, standalone or integrated with orthogonal techniques like SPR biophysical assays, we generate the data that drives your program forward. If commercial reagents are unavailable, our Protein Sciences team can produce custom reagents in-house.
Our Expertise in Target Classes
We have deep experience developing custom screening assays across a wide range of enzyme classes and targets:
We use advanced automation platforms to miniaturize assays, increase throughput, reduce costs, and improve data robustness. Assays can be run in 96, 384, or 1536-well formats with high precision—ideal for compound profiling.
Our PHERAstar® FSX multiwavelength microplate reader, considered an industry gold standard, delivers unmatched sensitivity and speed. It includes an Advanced Assay Stability system for stabilizing surrounding temperature and reducing evaporation for particularly temperature sensitive targets. Additional instrumentation includes the MSD QuickPlex for ECL immunoassays, Luminex MAGPIX for multiplex analyte detection, and Envision multimode readers.
Enzyme Kinetics
Understanding enzyme kinetics is essential to drug discovery. Our scientists are experts in characterizing kinetic profiles and mechanisms of action, delivering high-quality data to guide your program. We tailor assay formats to match your target and the intended mode of action for your modulator.
Figure 1. Biochemical screening data showing pIC50 tracker over 80 independent assays for a fluorescence polarization assay that was used as a primary screen to support a H2L to LO program over an 18-month period.
Figure 2. Biochemical screening data showing Z’ tracker over 80 independent assays for a fluorescence polarization assay that was used as a primary screen to support a H2L to LO program over an 18-month period.
Figure 3. The mechanism of action of an enzyme inhibitor can be determined from its effects on Michaelis-Menten kinetics. Here a non-competitive inhibitor lowers the Vmax but does not affect the Kₘ value.
Jonathan Welti, Adam Sharp, Nigel Brooks, Wei Yuan, Christopher McNair, Saswati N Chand, Abhijit Pal,…
Journal Papers
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
High-throughput biophysical solutions for binding, kinetics, and target engagement combining advanced technologies with deep expertise to guide drug discovery.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
Comprehensive target class solutions integrate advanced assays, structural biology, and medicinal chemistry to accelerate hit-to-lead and candidate selection.
